On March 13, 2020, Genentech and Amgen agreed to vacate all pre-trial deadlines and their April 20, 2020 trastuzumab biosimilar jury trial date, due to an issue with a document vendor. The parties’ stipulation was ordered by Judge Connolly on March 16, 2020. On March 18, because of the ongoing COVID-19 pandemic, the District of Delaware suspended all civil and criminal jury selections and jury trials scheduled to begin before April 30, 2020. This order indefinitely postpones the Genentech v. Amgen trial. Genentech alleges in the case that Amgen’s commercial marketing of KANJINTI (trastuzumab-anns), which Amgen launched in July 2019, infringes a number of patents.
